STATegics

STATegics is a biotechnology company based in Sunnyvale, California, focused on the discovery and development of small molecule therapeutics for rare neurodegenerative and neuromuscular diseases. The company specializes in creating small molecule mimetics of tissue-protective cytokines, specifically targeting the erythropoietin (EPO) and thrombopoietin (TPO) receptors. Their lead research efforts are directed toward Friedreich's ataxia (FA), where their agonists aim to increase frataxin expression to address the underlying cause of the disease. STATegics also maintains programs for Parkinson's disease and thrombocytopenia. The company has secured significant non-dilutive funding through grants from the NIH, the Department of Defense, and the Michael J. Fox Foundation. By leveraging its expertise in cytokine signaling, STATegics aims to provide oral, small molecule alternatives to traditional biologic therapies.